Ipatasertib for Patients Previously Treated with Androgen Deprivation Therapy
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Ipatasertib for Patients Previously Treated with Androgen Deprivation Therapy

Sponsor: Genentech, Inc.

Protocol GO27983: A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC0980) with Abiraterone Acetate Versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy. Patients will be required to wear a continuous glucose monitor for the first 25 days of treatment.